Arvinas, Inc. (ARVN) Stock Grade

About Arvinas, Inc.'s fundamentals

Arvinas is a biotechnology company with a market capitalization of $484.6 million that is currently unprofitable, reporting a net loss and a negative net margin of -30.8% in its latest annual statement. The company's revenue declined slightly by 0.3% year-over-year, indicating minimal growth momentum. With a P/E ratio of 516.1, the valuation is extremely elevated relative to earnings, though this metric is less meaningful given the company's loss-making status. Arvinas does not pay a dividend, which is typical for early-stage biotech companies prioritizing research and development investment.